Patents by Inventor Tanja Schulz-Gasch

Tanja Schulz-Gasch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9290451
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046631
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20160046637
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160016968
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 28, 2015
    Publication date: January 21, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier GAVELLE, Uwe GRETHER, Atsushi KIMBARA, Nettekoven MATTHIAS, Roever STEPHAN, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH
  • PYRIDOPYRAZINE COMPOUNDS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA
    Publication number: 20160002226
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing influenza. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 7, 2016
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
    Publication number: 20160002227
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 7, 2016
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20150376192
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 31, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, NETTEKOVEN MATTHIAS, RICKLIN FABIENNE, ROEVER STEPHAN, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
    Publication number: 20150344429
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: December 3, 2015
    Inventors: Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Fabienne RICKLIN, Stephan ROEVER, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH, Matthias WESTPHAL
  • SUBSTITUTED TRIAZOLE BORONIC ACID COMPOUNDS
    Publication number: 20150329565
    Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.
    Type: Application
    Filed: November 29, 2013
    Publication date: November 19, 2015
    Inventors: Stephen M. Lynch, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20150307452
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 2, 2013
    Publication date: October 29, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat FREI, Luca GOBBI, Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Tanja SCHULZ-GASCH
  • SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS
    Publication number: 20150299143
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.
    Type: Application
    Filed: November 29, 2013
    Publication date: October 22, 2015
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Stephen M. Lynch, Rainer E. Martin, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
  • NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20150299220
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist for use in the treatment of several disorders, such as pain, atherosclerosis and glaucoma.
    Type: Application
    Filed: December 4, 2013
    Publication date: October 22, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Baledi DHURWASULU, Uwe GRETHER, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Tanja SCHULZ-GASCH
  • PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
    Publication number: 20150299165
    Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: October 22, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefanie BENDELS, Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Ernst SCHAFFTER, Tanja SCHULZ-GASCH
  • Adamantyl derivatives as cannabinoid receptor 2 agonists
    Patent number: 9090615
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 28, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NEW AZACYCLIC COMPOUNDS
    Publication number: 20150148363
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS
    Publication number: 20150111886
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Glucocorticoid receptor antagonists
    Patent number: 8883786
    Abstract: The present invention relates to compounds of formula I wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jacques Bailly, Cornelia Hertel, Daniel Hunziker, Christian Lerner, Ulrike Obst Sander, Jens-Uwe Peters, Philippe Pflieger, Tanja Schulz-Gasch
  • Pyrrolidine derivatives
    Patent number: 8729061
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R7 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: May 20, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Tanja Schulz-Gasch
  • NEW AZACYCLIC COMPOUNDS
    Publication number: 20140005400
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
    Patent number: 8501768
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 6, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch